China Medical System Secures China NDA Approval for First Targeted Vitiligo Treatment
China Medical System Holdings Limited (CMS) has announced that its subsidiary, Dermavon Holdings Limited, has received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) of China for ruxolitinib phosphate cream to treat non-segmental vitiligo. This approval grants Dermavon full authorisation to commercialise the product across Mainland China. The cream is a…